Pradaxa Bleeding Lawsuits Continue to Mount
For nearly two years, the Pradaxa lawyers at Saiontz & Kirk, P.A. have been reviewing and evaluating potential product liability lawsuits on behalf of individuals who suffered severe and uncontrollable bleeding problems caused by the relatively new anticoagulant.
The number of new complaints filed nationwide continues to increase, but many individuals and families who may be entitled to compensation through a Pradaxa bleeding lawsuit still have not contacted a lawyer to make sure their legal rights are protected.
In the federal court system, nearly 1,500 complaints have been brought by individuals who suffered severe hemorrhage injuries or families of individuals who suffered a wrongful death from Pradaxa.
A small group of cases in the MDL are being prepared for early trial dates, which are expected to begin late next year and provide a gauge for how juries may respond to evidence that Boehringer Ingelheim withheld important information about the safety of Pradaxa and the lack of a reversal agent to allow doctors stop bleeding that may develop while using the medication.
Boehringner Ingelheim introduced Pradaxa (dabigatran) in October 2010, as the first member of a new class of anticoagulants. The medication was promoted for stroke prevention as a superior alternative to warfarin (sold under the brand name Coumadin), which has traditionally been the commonly used anticoagulant.
While Pradaxa may be easier to take then warfarin, which requires medical monitoring during treatment, what the drug maker failed to disclose is that doctors may be left unable to stop Pradaxa bleeding, as there is no reversal agent available.
Pradaxa bleeding problems may pose a more serious risk, since they are typically harder to stop. This is especially significant among patients with kidney problems who cannot filter Pradaxa out of their bloodstream as fast as those with normal kidney functions.
According to allegations raised in Pradaxa lawsuits pending throughout the United States, Boehringer Ingelheim placed their desire for profits before consumer safety by aggressively marketing the drug as superior to warfarin without adequately warning about the risk of bleeds or the lack of a reversal agent.
Obtain a Free Pradaxa Case Evaluation
The Pradaxa attorneys at Saiontz & Kirk, P.A. are no longer accepting new cases for individuals who suffered severe injuries associated with bleeding events after using the medication.